KPTI - Karyopharm granted orphan drug status by EC for Xpovio for myelofibrosis

• The European Commission has granted Karyopharm Therapeutics' ( NASDAQ: KPTI ) Xpovio (selinexor) orphan drug status for myelofibrosis ( MF ).
• The company is examining Xpovio (selinexor), a first-in-class XP01 inhibitor, as monotherapy in patients with previously treated MF, and in combination with Jakafi (ruxolitinib) in treatment-naïve patients.
• Xpovio was granted orphan drug status by the US FDA for the same indication earlier this year.
• In the US, the drug is approved for multiple myeloma and diffuse large B-cell lymphoma.
• Check out why Seeking Alpha contributor Biologics sees Karyopharm ( KPTI ) as a buy.

For further details see: